Zyla Life Sciences Accounts Receivable
Zyla Life Sciences had Accounts Receivable of $31.06 million as of 2020-03-31, per its 10-Q filed 2020-05-14.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2020-05-14
- 2020-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $31.06M.
- 2019-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $25.70M.
- 2019-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $26.58M.
- 2019-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $21.22M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2020-03-31 | $31.06M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $25.70M 10-Q · filed 2020-05-14 |
| 2019-09-30 | $26.58M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $21.22M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $39.94M 10-Q · filed 2019-05-17 |
| 2019-02-01 | $4.14M 10-Q · filed 2020-05-14 |
| 2019-01-31 | $4.14M 10-Q · filed 2020-05-14 |
| 2018-12-31 | $8.01M 10-K · filed 2020-03-26 |
| 2018-09-30 | $10.84M 10-Q · filed 2018-11-19 |
| 2018-06-30 | $9.08M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $14.98M 10-Q · filed 2018-05-10 |
| 2018-01-02 | $3.75M 10-Q · filed 2018-05-10 |
| 2018-01-01 | $3.75M 10-K · filed 2019-03-29 |
| 2017-12-31 | $4.12M 10-K · filed 2019-03-29 |
| 2017-09-30 | $5.61M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $5.11M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $5.41M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $1.11M 10-K · filed 2018-03-16 |
| 2016-09-30 | $3.89M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $820.00K 10-Q · filed 2016-08-05 |
| 2016-03-31 | $829.00K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $295.00K 10-K · filed 2017-03-13 |